In this article we provide an overview of Novartis and its current portfolio, and look at its pipeline of new drugs and areas of research interest. Copyright 2010 John Wiley & Sons, Ltd.doi:10.1002/fps.67NoneJohn Wiley & Sons, Ltd.
Novartis’s multiple sclerosis drug Kesimpta gained approval at the end of March. It will compete with Roche’s seller Ocrevus, which brought in SFr4.3bn last year. Both drugs have similar mechanisms, but Ocrevus is administered by infusion in hospitals twice a year while patients can inject ...
Novartis has previously had to pay fines for illegal methods of promoting its drugs. In 2010, the company agreed to pay $422 million to settle various civil and criminal charges. In October 2015, Novartis agreed to pay US $390 million for kickbacks to two pharmacies in order to promote ...
To settle these allegations,Novartis will pay $51.25 million. Second Settlement – Kickbacks to Doctors Then, in thesecond settlement, Novartis will pay $591.4 million to resolve False Claims Act (FCA) allegations that it paid kickbacks to entice doctors to prescribe several Novartis drugs, ...
resolution related to instances of mis- conduct at the Company between 2013 and 2015 with regard to certain generic drugs sold in the United States. The term of the DPA concluded in March 2023 and the underlying matter has been dismissed. Sandoz Inc. also finalized a resolution with the DOJ...
Novartis, facing the same problems as other large pharmaceutical companies, needs to find new drugs to bulk up its pipeline as patents near expiration on some of its blockbusters, including high-blood-pressure medication Diovan and cancer drug Gleevec, potentially threatening earnings growth. The acqu...
Some of the speaker events never took place, but Novartis still paid a fee to induce the speaker to prescribe Novartis drugs. Sales representatives were given monthly goals for the number of speaker programs and roundtables they were to conduct and for the number of meetings and events th...
Other drugs in the area include AbbVie’s Humira (adalimumab), which recorded 29 per cent of the market share that year. Both Enbrel and Humira are tumour necrosis factor (TNF) inhibitors and work in the same way to treat a variety of autoimmune conditions. Secukinumab has a different ...
The company based in Basel, Switzerland, has been counting on these new drugs to offset patent expirations, such as its blockbuster heart drug Diovan which lost U.S. protection in 2012. Also helping was a $900 million pretax gain from selling part of its diagnostics business to the Spanish...
body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination (i.e., other drugs being administered to the patient) and the severity of the particular disease undergoing therapy, as well as the judgment of the prescribing medical pr...